4 Biotechs Facing Do-or-Die Catalysts in December Post author:Sam Post published:December 5, 2017 Post category:BioPharma As 2018 winds down, it’s not over for some biopharma companies. Source: BioSpace You Might Also Like Why This Seattle Biotech Could be an M&A Target January 18, 2018 Why This Maryland Biotech Could Double Its Stock by 2018 November 19, 2017 Integrated DNA Technologies Launches First Cas9 Enzyme That Drastically Reduces CRISPR Off-Target Effects Without Significant Loss Of On-Target Activity July 31, 2017
Integrated DNA Technologies Launches First Cas9 Enzyme That Drastically Reduces CRISPR Off-Target Effects Without Significant Loss Of On-Target Activity July 31, 2017
